<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="3759">
  <stage>Registered</stage>
  <submitdate>13/12/2012</submitdate>
  <approvaldate>13/12/2012</approvaldate>
  <nctid>NCT01751269</nctid>
  <trial_identification>
    <studytitle>Safety, Tolerability, Pharmacokinetics of Intravenous RPX7009 in Healthy Adult Subjects</studytitle>
    <scientifictitle>A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Ascending Single and Multiple-Dose Study of the Safety, Tolerability, Pharmacokinetics of Intravenous RPX7009 in Healthy Adult Subjects.</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>Rempex 402</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Healthy Volunteers</healthcondition>
    <healthcondition>Bacterial Infections</healthcondition>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - RPX7009
Treatment: drugs - Placebo

Experimental: Ascending Single and Multiple dose of RPX7009 - Ascending Single and Multiple dose of RPX7009

Placebo Comparator: Normal Saline - Ascending Single and multiple dose of normal saline.


Treatment: drugs: RPX7009
Ten (10) cohorts of 8 subjects (6 active and 2 placebo) are planned for evaluation.

Treatment: drugs: Placebo
Ten (10) cohorts of 8 subjects (6 active and 2 placebo) are planned for evaluation.

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Safety from baseline through the end of the study. - Number of patients with adverse events; assessed by patient reporting, collection of vital signs, ECGs and absolute values and changes over time of hematology, chemistry and urinalysis.</outcome>
      <timepoint>Study Day 1 to Day 13.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Composite of PK parameters RPX7009 &amp; placebo following single dose administration. - Plasma AUC0-t, AUC0-inf, Cmax, and Tmax.</outcome>
      <timepoint>Study Day 1 to Day 12</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Healthy adult males and/or females (of Non Child-bearing potential), 18 to 55 years of
             age

          -  Body mass index (BMI) = 18.5 and = 29.9 (kg/m2) and weight between 55.0 and 100.0 kg
             (inclusive).

          -  Medically healthy with clinically insignificant screening results

          -  Non-tobacco/nicotine-containing product users for a minimum of 6 months prior to Day
             1.

          -  Sexually abstinent or use acceptable methods of birth control</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>55</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>-  History or presence of significant cardiovascular, pulmonary, hepatic, renal,
             hematological, gastrointestinal, endocrine, immunologic, dermatologic, neurological,
             or psychiatric disease.

          -  History or presence of alcoholism or drug abuse within the 2 years prior to Day 1.

          -  Documented hypersensitivity reaction or anaphylaxis to any medication.

          -  Use of any over-the-counter (OTC) medication, including herbal products and vitamins,
             within the 7 days prior to Day 1. Up to 2 grams per day of acetaminophen is allowed
             for acute events at the discretion of the PI.

          -  Plasma donation within 7 days prior to Day 1.

          -  Subjects who have any abnormalities on laboratory values at screening or check-in (Day
             -1).</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2 />
    <masking3 />
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate />
    <actualstartdate>1/12/2012</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>80</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/07/2013</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>SA</recruitmentstate>
    <hospital>CMAX - Adelaide</hospital>
    <postcode>5000 - Adelaide</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Rempex Pharmaceuticals (a wholly owned subsidiary of The Medicines Company)</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>RPX7009 (beta-lactamase inhibitor) is being studies in combination with a carbapenem biapenem
      to treat bacterial infections, including those due to multi-drug resistant bacteria.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01751269</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Jefferey Loutit, MBChB</name>
      <address>Sponsor GmbH</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>